Report
No Data Yet
Elevance Health Inc. reported Q2 earnings of $7.45 per share, beating the $6.18 consensus by 20.6 percent. "The results reflect continued execution across our diversified health platform," the Indianapolis-based company said in its earnings release. Revenue came in at $50.47 billion, or $49.83 billion on an adjusted basis, above the $48.45 billion analysts had expected. Net income was $1.46 billion, compared with $1.94 billion a year earlier when the company earned $8.84 per share. | Metric | Actual | Consensus | Beat/Miss | |--------|--------|-----------|-----------| | Revenue (adjusted) | $49.83B | $48.45B | +2.9% | | EPS | $7.45 | $6.18 | +20.6% | The health insurer held its full-year outlook at $27 per share. The guidance implies a sharp acceleration from the first half, when the company earned a combined $13.70 per share, suggesting management expects stronger performance in the back half of the year. Elevance, one of the largest US managed-care companies by membership, operates Blue Cross and Blue Shield plans in 14 states and serves more than 45 million members. The earnings beat comes as the broader managed-care sector faces pressure from rising medical costs and tighter Medicaid reimbursement rates. Rivals UnitedHealth Group Inc. and Humana Inc. have also reported mixed results this earnings season, making Elevance's above-consensus performance a relative bright spot. The earnings beat signals that Elevance's cost controls and premium pricing are holding up better than peers. Investors will watch the company's investor day later this year for updated margin targets and membership growth forecasts. This article is for informational purposes only and does not constitute investment advice.
**Elevance Health beat quarterly profit estimates as medical costs eased, lifting its full-year earnings forecast.** Elevance Health reported $1.45 billion in second-quarter net income, beating analyst estimates, as easing medical costs in some health plans drove an improved full-year outlook. The Indianapolis-based insurer earned $6.71 per share, topping the $6.18 consensus estimate compiled by Wall Street analysts, though net income fell 16.6% from $1.74 billion, or $7.72 per share, a year earlier. "Second quarter results exceeded our expectations, supported by disciplined execution and improved operating performance across our diversified portfolio," Chief Executive Officer Gail K. Boudreaux said. The company attributed the results partly to "favorable benefit expense performance and an approximately $0.80 per share net below-the-line benefit." Revenue rose 1.4% to $50.47 billion, above the $48.45 billion forecast. Operating revenue reached $49.8 billion, up $400 million from the prior year, driven by higher premium yields in the health benefits segment and growth in CarelonRx product revenue. The benefit expense ratio — the share of premium revenue spent on medical claims — widened to 89.7% from 88.9% a year earlier, driven by elevated costs in government-backed plans including Medicare Advantage and Medicaid, partially offset by improved performance in individual ACA plans. Elevance raised its full-year adjusted earnings forecast to at least $27 per share for 2026, up from a prior outlook of at least $19.85, and said it expects to return to at least 12% adjusted EPS growth in 2027. The company also lifted its 2026 guidance to at least $20.10 per share from at least $19.85, reflecting confidence in the second-half outlook. Membership fell to 44.9 million from 45.6 million a year earlier, a decline of 1.5%, driven by losses in Medicare Advantage, Medicaid, and employer-group risk plans. Premium revenue dropped 3.3% to $39.9 billion, partially offset by a 4.7% increase in product revenue to $6.32 billion and a 6% gain in service fees to $2.24 billion. Net investment income fell 8.1% to $446.9 million. Analysts had modeled total medical membership of 44.82 million, Medicare Advantage enrollment of 1.87 million, and Medicaid membership of 8.23 million. The results come as the health insurance sector navigates elevated medical costs that have persisted since the pandemic. Rivals including UnitedHealth Group and Humana have reported similar pressure from Medicare Advantage members catching up on deferred care. Health insurers historically target benefit expense ratios in the mid-to-low 80s, a level that has remained largely out of reach for most plans over the past year. The last time the industry saw sustained ratios below 85% was before the pandemic, when utilization patterns were more predictable. Elevance, the nation's second-largest health insurer behind UnitedHealth Group's UnitedHealthcare unit, operates Anthem-branded Blue Cross and Blue Shield plans across 14 states. It also manages Medicaid contracts in multiple states and sells individual coverage through the Affordable Care Act marketplaces. Its Carelon healthcare services business contributed to revenue growth, with the company planning accelerated investments in medical cost management, member experience, and provider connectivity. Boudreaux said the company is "raising our 2026 adjusted guidance to at least $27.00 and accelerating targeted investments in the capabilities that matter most: medical cost management, member experience, provider connectivity, operating efficiency, and Carelon's value-based solutions." The moves are designed to "strengthen how we operate, improve consistency over time, and reinforce our confidence in returning to at least 12% adjusted EPS growth in 2027 off our 2026 earnings baseline." The forward guidance implies that management sees the current cost cycle peaking, with the benefit expense ratio expected to improve as investments in cost management take effect. If Elevance achieves its 2027 target, it would mark a return to the growth trajectory the company delivered before the post-pandemic utilization surge disrupted margins across the managed-care sector. *This article is for informational purposes only and does not constitute investment advice.*
**UnitedHealth Group and Elevance Health report quarterly earnings on July 15 and 16, testing whether the health insurance sector's 28% year-to-date rally can withstand a second-quarter cost check.** UnitedHealth Group and Elevance Health report quarterly results this week, with the two largest US health insurers by market capitalization facing investor scrutiny on medical cost trends after a first quarter that rewarded disciplined pricing. Elevance Health kicks off the week on July 15, followed by UnitedHealth on July 16 and CVS Health on Aug. 5. The trio collectively covers more than 100 million members across commercial insurance, Medicare Advantage and Medicaid. "The first quarter showed that repricing is working, but the question is whether those margins hold into the back half of the year," said Sam Goldstein, healthcare analyst at Edgen. "The market is pricing in a beat for UnitedHealth, but Elevance has more to prove after its benefit ratio spiked in the fourth quarter." UnitedHealth enters the week with momentum. The Minnetonka, Minnesota-based insurer delivered first-quarter adjusted EPS of $7.23, beating the $6.60 consensus by 9.55 percent, while its medical care ratio improved 90 basis points to 83.9 percent. Operating cash flow jumped 63.34 percent to $8.9 billion. Management raised full-year 2026 adjusted EPS guidance to above $18.25 from a prior above-$17.75 target. Prediction market Polymarket assigns a 71 percent probability of a second-quarter beat. Elevance Health faces a higher bar. The Indianapolis-based insurer is expected to report EPS of $6.18, down 30.1 percent from a year earlier, on revenue of $48.45 billion, a 2 percent decline. Its fourth-quarter 2025 benefit expense ratio hit 93.5 percent, meaning the company paid out 93.5 cents of every premium dollar on medical claims, swinging its Health Benefits segment to a loss. The Zacks Earnings ESP, which measures the gap between the most recent analyst estimate and the consensus, stands at negative 0.42 percent for Elevance, suggesting analysts have turned slightly more bearish ahead of the print. **What the results mean for the sector** The earnings come at a pivotal moment for managed care stocks. The S&P 500 Managed Health Care index has gained roughly 28 percent year to date, outpacing the broader S&P 500's 10 percent advance, as investors bet that 2025's cost pressures were a one-time event driven by elevated outpatient utilization and Medicare Advantage rate resets. Humana's experience shows the risk of getting it wrong. The Louisville-based insurer guided full-year 2026 adjusted EPS to at least $9.00, down from $17.14 in fiscal 2025 — a 47 percent decline driven by Star Ratings damage that reduced Medicare Advantage quality bonus payments. UnitedHealth, by contrast, carries no such Star Ratings overhang and operates with the scale advantage of a $388.9 billion market cap. For UnitedHealth, the key metric is the medical care ratio. At 83.9 percent in the first quarter, it sits well below Elevance's fourth-quarter 93.5 percent and Humana's elevated levels. The company plans roughly $8.0 billion in dividends and $2.5 billion in buybacks in 2026, with a $2 billion buyback tranche completed by the end of the second quarter. The stock's 2.15 percent dividend yield on an $8.84 annual payout offers income support. For Elevance, the focus will be on whether the benefit expense ratio has improved from the fourth-quarter peak and whether management can stabilize the Health Benefits segment. The company has beaten consensus EPS estimates in three of the past four quarters, including a 17.79 percent surprise in the most recent reported period. The results will set the tone for the sector heading into the second half of 2026. A clean print from both insurers could extend the rally; a miss — particularly on medical cost trends — could trigger a sector-wide reassessment of margin expectations. This article is for informational purposes only and does not constitute investment advice.
**Defensive sector rotation is pulling money into healthcare as US-Iran military escalation pushes the Dow down more than 500 points and oil above $85 a barrel.** US-Iran tensions escalated sharply this week after explosions hit Iran's strategic port of Chabahar as part of "Operation Epic Fury," a joint US-Israel military campaign targeting Iranian military infrastructure. The S&P 500 fell 1.8% on Tuesday, its worst single-day drop in three months, while Brent crude surged past $85 a barrel as traders priced in supply disruption risk from the Strait of Hormuz. The VIX, Wall Street's fear gauge, jumped to 24.6, its highest since April. "Investors are rotating out of cyclical exposure and into sectors with inelastic demand, and healthcare fits that profile perfectly," said Sam Goldstein, healthcare analyst at Edgen. "When geopolitical risk spikes, hospital operators and managed-care companies offer revenue visibility that energy or industrial stocks cannot match." The defensive rotation thesis has historical precedent. During the 2020 Iran-US confrontation after the Qassem Soleimani strike, the Health Care Select Sector SPDR Fund (XLV) outperformed the S&P 500 by 4.2 percentage points over the following month. The current escalation carries additional weight: prediction markets now price a 29% probability of Iran closing its airspace by July 31, up from 11% a day earlier, while the implied chance of the Iranian regime falling before 2027 rose to 8.5%. **Tenet Healthcare: Hospital exposure with a valuation discount** Tenet Healthcare Corp. (NYSE: THC) operates 60 hospitals and more than 550 outpatient centers across the US, giving it direct exposure to elective procedure volumes that tend to remain stable regardless of the macro environment. The stock trades at roughly 8 times forward earnings, a discount to the broader healthcare services peer group that typically commands 12 to 15 times. Tenet's hospital occupancy rates have held above 65% through the first half of 2026, and its ambulatory surgery center network continues to capture market share as procedures migrate out of hospital settings. **Elevance Health: Managed-care stability with membership growth** Elevance Health Inc. (NYSE: ELV), formerly Anthem, is one of the largest managed-care organizations in the US with more than 47 million medical members across its Blue Cross Blue Shield licenses and commercial plans. The company reported a medical loss ratio of 86.2% in its most recent quarter, meaning it paid out roughly 86 cents of every premium dollar on medical claims, leaving a sustainable margin. Elevance trades at about 11 times forward earnings, below its five-year average of 14 times, as investors have discounted the sector over Medicaid redetermination uncertainty. That overhang is now largely priced in, analysts say, and the stock's 1.4% dividend yield adds a total-return cushion during volatile periods. **Aveanna Healthcare: Home health with demographic tailwinds** Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH) provides home nursing, therapy, and hospice services to more than 50,000 patients across 33 states. The home health sector benefits from structural demand growth as the US population ages — the 65-and-over cohort is projected to grow to 80 million by 2030 from 56 million in 2020, according to Census Bureau data. Aveanna trades at roughly 0.5 times revenue, a fraction of larger peers, reflecting its smaller scale and higher leverage. The company has been working to reduce its debt load, and any positive catalyst on that front could drive outsized returns. **What's at stake for the broader market** The US-Iran confrontation introduces a binary risk for equity markets. If tensions de-escalate — through diplomatic channels or a ceasefire — the defensive rotation could unwind quickly, sending capital back into cyclicals and growth stocks. But if the conflict widens to disrupt oil flows through the Strait of Hormuz, through which about 20 million barrels of crude pass daily, the macro shock would likely deepen the selloff and extend the bid for defensive sectors. The next key date is July 31, when Iran's airspace closure probability will be tested against actual developments on the ground. This article is for informational purposes only and does not constitute investment advice.